Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynne Garrity-Ryan

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Jac-Antimicrobial Resistance|January 6, 2022
Sub-growth-inhibitory concentrations of omadacycline inhibit <i>Staphylococcus aureus</i> haemolytic activity <i>in vitro</i>Alisa W Serio, S Ken Tanaka, Kelly Wright, et al.
The Journal of Clinical Investigation|January 20, 2007
The ubiquitin ligase Cbl-b limits Pseudomonas aeruginosa exotoxin T-mediated virulencePriya Balachandran, Leonard Dragone, Lynne Garrity-Ryan, et al.
Antimicrobial Agents and Chemotherapy|November 29, 2017
Safety and Pharmacokinetics of the Aminomethylcycline Antibiotic Omadacycline Administered to Healthy Subjects in Oral Multiple-Dose RegimensLu Ann Bundrant, Evan Tzanis, Lynne Garrity-Ryan, et al.
International Journal of Antimicrobial Agents|December 16, 2020
Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild-to-moderate renal impairmentOliver A Cornely, Thomas M File, Lynne Garrity-Ryan, et al.
Antimicrobial Agents and Chemotherapy|November 22, 2017
Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal FunctionJolene K Berg, Evan Tzanis, Lynne Garrity-Ryan, et al.
Antimicrobial Agents and Chemotherapy|March 13, 2019
Pharmacokinetics, Safety, and Clinical Outcomes of Omadacycline in Women with Cystitis: Results from a Phase 1b StudyJ Scott Overcash, Pouru Bhiwandi, Lynne Garrity-Ryan, et al.
Antimicrobial Agents and Chemotherapy|July 12, 2017
Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult SubjectsMark H Gotfried, Karolyn Horn, Lynne Garrity-Ryan, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 23, 2021
Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumoniaAntoni Torres, Lynne Garrity-Ryan, Courtney Kirsch, et al.
The Lancet. Infectious Diseases|September 3, 2019
Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trialWilliam O'Riordan, Carrie Cardenas, Elliot Shin, et al.
The New England Journal of Medicine|February 7, 2019
Omadacycline for Acute Bacterial Skin and Skin-Structure InfectionsWilliam O'Riordan, Sinikka Green, J Scott Overcash, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Jac-Antimicrobial Resistance|January 6, 2022
Sub-growth-inhibitory concentrations of omadacycline inhibit <i>Staphylococcus aureus</i> haemolytic activity <i>in vitro</i>Alisa W Serio, S Ken Tanaka, Kelly Wright, et al.
The Journal of Clinical Investigation|January 20, 2007
The ubiquitin ligase Cbl-b limits Pseudomonas aeruginosa exotoxin T-mediated virulencePriya Balachandran, Leonard Dragone, Lynne Garrity-Ryan, et al.
Antimicrobial Agents and Chemotherapy|November 29, 2017
Safety and Pharmacokinetics of the Aminomethylcycline Antibiotic Omadacycline Administered to Healthy Subjects in Oral Multiple-Dose RegimensLu Ann Bundrant, Evan Tzanis, Lynne Garrity-Ryan, et al.
International Journal of Antimicrobial Agents|December 16, 2020
Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild-to-moderate renal impairmentOliver A Cornely, Thomas M File, Lynne Garrity-Ryan, et al.
Antimicrobial Agents and Chemotherapy|November 22, 2017
Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal FunctionJolene K Berg, Evan Tzanis, Lynne Garrity-Ryan, et al.
Antimicrobial Agents and Chemotherapy|March 13, 2019
Pharmacokinetics, Safety, and Clinical Outcomes of Omadacycline in Women with Cystitis: Results from a Phase 1b StudyJ Scott Overcash, Pouru Bhiwandi, Lynne Garrity-Ryan, et al.
Antimicrobial Agents and Chemotherapy|July 12, 2017
Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult SubjectsMark H Gotfried, Karolyn Horn, Lynne Garrity-Ryan, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 23, 2021
Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumoniaAntoni Torres, Lynne Garrity-Ryan, Courtney Kirsch, et al.
The Lancet. Infectious Diseases|September 3, 2019
Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trialWilliam O'Riordan, Carrie Cardenas, Elliot Shin, et al.
The New England Journal of Medicine|February 7, 2019
Omadacycline for Acute Bacterial Skin and Skin-Structure InfectionsWilliam O'Riordan, Sinikka Green, J Scott Overcash, et al.
Pageof 2